ReviewVaccine2019
The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations.
Review in Vaccine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 55 citations in OpenAlex.
- Alternative approaches to phase III clinical trials for vaccine efficacy and licensure: the role of real-world evidence - a meeting report.Biologicals : journal of the International Association of Biological Standardization · 2026Article
- Serum inflammatory and coagulation markers in GBS infection and adverse pregnancy outcomes.Biomarkers in medicine · 2026Article
- A surrogate endpoint-based provisional approval causal roadmap, illustrated by vaccine development.Biostatistics (Oxford, England) · 2025Article
- Economic evaluation of prenatal GBS immunization in China: A modeling analysis.Human vaccines & immunotherapeutics · 2025Article
- NovelmBio · 2025Article
- Group B Streptococcus (GBS) Carriage in Pregnant Women: Possible Emergence of Rare Serotypes and Antibiotic Resistance in Neonatal Disease.Microorganisms · 2025Article
- Review
- Development and validation of a 6-plex Luminex-based assay for measuring human serum antibodies to group B streptococcus capsular polysaccharides.Human vaccines & immunotherapeutics · 2024Article
- Genomic and functional determinants of host spectrum in Group B Streptococcus.PLoS pathogens · 2024Article
- Emergence of High-Level Gentamicin Resistance inAntibiotics (Basel, Switzerland) · 2024Article
- Article
- Neonatal Group B Streptococcus Disease.Pediatrics in review · 2024Review
- GBS vaccines in the UK: a round table discussion.F1000Research · 2024Article
- Vaccines forFrontiers in immunology · 2024Review
- Preparing for Group BHuman vaccines & immunotherapeutics · 2023Article
- Article
- Strategies to Prevent Early and Late-Onset Group BPathogens (Basel, Switzerland) · 2023Review
- Early-onset group B streptococcal disease in African countries and maternal vaccination strategies.Frontiers in public health · 2023Article
- Understanding the epidemiology of iNTS disease in Africa in preparation for future iNTS- vaccine studies in endemic countries: Seroepidemiology in Africa of iNTS (SAiNTS) Study Protocol: Malawi site [Version 9.0].Wellcome open research · 2023Article
- Molecular Epidemiology of Group B Streptococcus Colonization in Egyptian Women.Microorganisms · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 11 institutions in 6 countries.
Funding
Abstract
The development of a group B Streptococcus (GBS) vaccine for maternal immunization constitutes a global public health priority, to prevent GBS-associated early life invasive disease, stillbirth, premature birth, maternal sepsis, adverse neurodevelopmental consequences, and to reduce perinatal antibiotic use. Sample size requirements for the conduct of a randomized placebo-controlled trial to assess vaccine efficacy against the most relevant clinical endpoints, under conditions of appropriate ethical standards of care, constitute a significant obstacle on the pathway to vaccine availability. Alternatively, indirect evidence of protection based on immunologic data from vaccine and sero-epidemiological studies, complemented by data from opsonophagocytic in vitro assays and animal models, could be considered as pivotal data for licensure, with subsequent confirmation of effectiveness against disease outcomes in post-licensure evaluations. Based on discussions initiated by the World Health Organization we present key considerations about the potential role of correlates of protection towards an accelerated pathway for GBS vaccine licensure and wide scale use. Priority activities to support progress to regulatory and policy decision are outlined.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.